Previous 10 | Next 10 |
Y-MAbs Therapeutics, Inc. (YMAB) Q4 2021 Earnings Conference Call February 25, 2022 09:00 ET Company Participants Thomas Gad - Founder, Chairman & President Claus Møller - Chief Executive Officer Bo Kruse - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of...
Y-mAbs Therapeutics press release (NASDAQ:YMAB): FY GAAP EPS of -$1.28 misses by $0.59. Revenue of $34.9M (+68.2% Y/Y) beats by $24.08M. For further details see: Y-mAbs Therapeutics GAAP EPS of -$1.28 misses by $0.59, revenue of $34.9M beats by $24.08M
Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND submission to the FDA for first SADA construct Appointed Sue Sm...
NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the ...
Gainers: Kaival Brands Innovations KAVL +42%. Y-mAbs Therapeutics YMAB +29%. China Online Education (NYSE:COE) +24%. Mr. Cooper COOP +20%. Zillow Z +19%. Carpenter Technology (NYSE:CRS) +19% Zillow ZG +18%. Eqonex EQOS +17%. Bloom Energy BE +17%. XPEL (...
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
Y-mAbs Therapeutics (NASDAQ:YMAB) is trading ~9% higher in the pre-market on Friday after the company announced its plans to resubmit the U.S. marketing application for omburtamab by the end of Q2 2022. The decision followed a Pre-Biologics License Application (“pre-BLA”) meetin...
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...